AB-Biotics proves the efficiency of the use of pharmacogenetics as a treatment of depression
AB-Biotics just published in the journal Pharmaceutics the results from a meta-analysis that prove the clinical utility of Neurofarmagen®, a pharmacogenetics tool, to select and guide the prescription of psychiatric drugs in adult patients with major depression, especially moderate-severe. For the development of this study, three clinical studies that were carried out...
The Board of Directors calls for an Extraordinary Shareholders Meeting to be held on October 4th
The Board of Directors of AB-Biotics calls for an Extraordinary Shareholders Meeting to be held on October 4th at the Barcelona Stock Exchange to approve the proposal to delist all the company’s shares from the Alternative Stock Market (MAB). In the event that the proposal is approved, Kaneka will leave an opening...
Kaneka has successfully completed its voluntary takeover bid and taken control of AB-Biotics, holding 66.33% of its capital
AB-Biotics has informed the CNMV that Kaneka Europe Holding has successfully completed the voluntary takeover bid for the 60.24% (7.583.025) of the company it did not yet possess. That bid has been accepted by shareholders representing 44.11% of that percentage. Kaneka now holds another 26.57% of the capital of the Spanish company...
The Board of Directors request a fairness opinion about the price offered by Kaneka
At a meeting held yesterday, the Board of Directors of the Company has adopted, unanimously (the directors designated by Kaneka Europe Holding Company NV –“Kaneka” abstaining from participating), among others, the following decisions: These directors appreciate that the offer formulated by Kaneka entails a commitment with the Company’s entrepreneurial In...
Kaneka launches a takeover bid for 100% of AB-Biotics
AB-Biotics announced today that Kaneka Europe Holding Company has launched a voluntary takeover bid for 100% of the share capital of the company excluding the shares it already possesses, consequently valuing the company at €63 million. The Japanese company is currently the biggest shareholder in AB-Biotics, owning 39.76% of its capital. The...
We celebrate #WorldMicrobiomeDay today, June 27th
Today, June 27th, we join the entire world’s scientific community in celebrating #WorldMicrobiomeDay. The microbiome is the group of microorganism colonies that live inside humans (bacteria, fungi, viruses, etc.). Researchers are exploring how these communities of organisms co-exist with each other, with us and our environment. The 2019 #WorldMicrobiomeDay theme is ‘Antibiotic Resistance’....
AB-Biotics to attend the IPA World Congress + Probiota Americas, the world’s premier probiotics and prebiotics event
AB-Biotics will actively participate in the IPA World Congress + Probiota Americas organized by NutraIngredients-USA, which will take place in Vancouver, Canada, from June 24th to 26th. The congress is the premier annual event in the prebiotics, probiotics, and microbiota market focused on the pharma and food industries. AB-Biotics will have a...
AB-BIOTICS attends to ESPGHAN Annual Meeting 2019 for the first time
AB-Biotics attended for the first time to ESPGHAN 2019 Annual Meeting (The European Society for Paediatric Gastroenterology Hepatology and Nutrition) held last week in Glasgow (Scottland). ESPGHAN is a multi-professional organization whose aim is to promote the health of children with special attention to the gastrointestinal tract, liver and nutritional status, through...
AB-Biotics earned 1,2 million euros in 2018
As reported by the company, it increased its turnover by 65% in 2018 at the end of the year with revenues of 11,8 million euros. The company's EBITDA reached 2 million euros during the previous year, which represents a growth of 844% over 2017. The founders and executive directors of the company,...